Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TAR-200 with or without cetrelimab versus intravesical BCG in BCG-naive high-risk non-muscle-invasive bladder cancer
CTR20222887Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) comparing TAR-200 + cetrelimab, TAR-200 monotherapy and Intravesical BCG (3 arms). Primary endpoint: Event-free survival. Started Jun 2023; status: active.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimabbcg vaccine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20222887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222887.